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ABSTRACT 
 
Aims - Left ventricular (LV) mechanics have been extensively investigated in heart 
failure with preserved ejection fraction (HFpEF) overshadowing for a long time the 
potential role of left atrium (LA) in that setting. Soluble suppression of 
tumorigenicity-2 receptor (ST2) is a novel biomarker of pro-fibrotic burden in HF. 
We hypothesized that due to the thinner LA wall the fibrotic myocardial changes in 
HFpEF as indicated by elevated ST2 levels might more readily be reflected by 
impairments in the LA rather than the LV performance.   
Methods and Results - In 86 patients with HFpEF, enrolled in the Karolinska Rennes 
(KaRen) biomarker prospective sub-study, global LA strain (GL-LS) along with other 
echocardiographic as well as hemodynamic parameters and ST2 levels were measured.  
ST2 levels were inversely associated with LA-GS (r=-0.30, p=0.009), but not with LA 
size, LV geometry, systolic or diastolic LV function (p>0.05 for all). Furthermore, 
symptom severity correlated with ST2 and LA-GS, but not with LV structural or 
functional indices. Finally, during a median 18-month follow-up, LA-GS 
independently predicted the composite endpoint of HF hospitalization and all-cause 
mortality, even after adjustment for potential clinical and cardiac mechanical 
confounders, including LV global longitudinal strain and filling pressures (odds ratio: 
4.15; confidence interval: 1.2-14, p= 0.023). 
Conclusions - Reduced LA-GS, but not LV functional systolic and diastolic 
parameters were associated with the pro-fibrotic ST2 marker, HF symptoms and 
outcome in HFpEF. 
ClinicalTrials.gov. NCT00774709 
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INTRODUCTION 
Heart failure with preserved ejection fraction (HFpEF) accounts for up to half of 
patients with heart failure (HF),[1, 2] with a prognosis comparable to that of HF with 
reduced ejection fraction (EF)[1] and an increasing prevalence.  
For a long time, investigations aiming to uncover the pathophysiology underlying 
HFpEF have focused on left ventricular (LV) mechanics; however no pathognomonic 
LV functional or structural alterations have been identified. While LV hypertrophy is 
common in HFpEF, nearly half of the HFpEF patients show no signs of 
hypertrophy.[2] Similarly, although increased LV stiffness is typical in this patient 
population,[3, 4] it may also occur in subjects without clinical signs and symptoms of 
HF.[5] Furthermore, whereas LV diastolic dysfunction is considered as a hallmark of 
HFpEF, abnormal diastolic LV performance is an almost universal finding in elderly 
patients without HFpEF,[5] which underscores the significance of other mechanisms 
in the pathophysiology of HFpEF.  
Recently, a subtle shift in the focus of interest in the HFpEF field has occurred with 
an increasing number of studies investigating the role of the left atrium (LA) rather 
than that of the LV in the HFpEF.[6-9] Elevated filling pressures and subsequent LA 
dilation is a characteristic finding in HFpEF. The degree LA enlargement reflects 
disease chronicity [10] and is prognostic in HFpEF.[9] Importantly, apart from the 
structural remodeling, increased LA stiffness has also been demonstrated in HFpEF, 
which further aggravates the elevated LA pressures, particularly during exertion.  
Increasing evidence supports the concept that HFpEF ultimately develops on the basis 
of a pro-inflammatory state triggered by comorbidities.[11] The soluble suppression 
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of tumorigenicity-2 receptor (ST2) is an established biomarker of inflammation and 
fibrosis with an emerging role in the diagnosis and prognostication of HF. In the 
context of HF, ST2 expression is thought to be triggered by myocardial stretch and 
consequent fibrosis.[12] In patients with reduced EF, ST2 has superior prognostic 
power compared to conventional biomarkers such as N-terminal pro-brain natriuretic 
peptide (NT-proBNP).[13] Patients with HFpEF also demonstrate elevated ST2 
levels. Interestingly however, in this condition no significant correlation between ST2 
levels and LV structure or function has been found.[14] 
As HFpEF is postulated to develop as a result of a systemic inflammatory reaction, 
we hypothesized that the LA, given its much thinner wall, is likely to be more 
susceptible to fibrotic changes as compared to the LV. Thus, early signs of the 
disease, as indicated by elevated ST2 levels, might more promptly manifest in altered 
LA mechanics, rather than in impaired LV performance. Accordingly, employing 
information from the biomarker Karolinska Rennes (KaRen) prospective, multicentre 
substudy we tested the hypothesis that in HFpEF (1) plasma ST2 levels correlate with 
LA function; and (2) impaired LA function is associated with worse outcomes. 
 
MATERIALS AND METHODS 
Study population 
The study included 86 HFpEF patients enrolled in the pre-speciﬁed KaRen Biomarker 
Study which comprised a sub-study of the Karolinska-Rennes (KaRen) prospective, 
observational, multicentre study.[15] Patients admitted for acute HF symtoms, NT-
proBNP > 300 ng/L and LVEF ≥45% were enrolled between May 2007 and December 
2011. 4–8 weeks after enrolment, when patients were in a stable condition, blood 
samples were taken and clinical investigations, including echocardiography, were 
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performed. The patients were followed until September 2012 when vital status was 
assessed by telephone contact or by the Swedish National Patient and Population 
Registers and then centrally adjudicated. All HF hospitalizations were adjudicated 
and defined according to clinical judgment by the local specialist investigator and 
additionally centrally validated to confirm the presence of HF at hospitalization. 
The primary outcome was the composite of time to death from any cause or ﬁrst 
hospitalization for HF (Figure S1).  
 
Biomarker assays 
Fasting blood samples were taken from subjects in a stable condition and euvolemic 
state, collected in chilled EDTA tubes, immediately centrifuged at 4°C and stored in 
aliquots at −70°C until analysis. NT-proBNP was analyzed by proBNPII (Roche 
Diagnostics, Bromma, Sweden). Plasma ST2 levels were measured by the Presage 
ST2 Assay (Critical Diagnostics, San Diego, California). Estimated glomerular 
filtration rate (eGFR) was calculated according to the MDRD study equation: 
(eGFR=175 x [creatinine]− 1.154 x [age] − 0.203 x 0.742 [if Female] mL/min/ 1.73; 
Creatinine in mg/dL, age in years. 
 
Echocardiographic data 
All subjects underwent transthoracic echocardiography using a Vivid-7 system (GE 
Ultrasound, Horten, Norway) equipped with a 2.5 MHz matrix array transducer. 
Images were analyzed offline (EchoPAC PC, version 2.0 GE Ultrasound, Waukesha, 
Wisconsin) by a single echocardiographer, blinded to the patients´ clinical data. Stroke 
volume index (SVi) was measured by Doppler method. For LA volumetric analysis, the 
method of disk method was used. Myocardial deformation was analyzed by 2 dimensional 
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speckle tracking, using dedicated software designed for the LV and LA, respectively 
(TomTec Imaging Systems, Unterschleissheim, Germany). LV global longitudinal strain (LV-
GLS) was calculated as the average of longitudinal strain measured in 12 segments obtained 
from the apical 4- and 2-chamber views. LA global strain (LA-GS) was measured in the 
apical 2-chamber view, according to the manufacturer’s recommendations. The LA 
endocardial border was traced so that the LA appendage and pulmonary veins were excluded. 
LA reservoir function was estimated by peak LA-GS during ventricular systole. All 
measurements were averaged over 3 cardiac cycles. At the time of echocardiographic 
examination 21 patients were in atrial fibrillation (AF). In these cases, measurements were 
averaged over 5 cycles. In case of significant foreshortening of the cavity or poor tracking 
quality, the measurements were considered unreliable and excluded from the analysis (n=7). 
Intra-observer variability for LA-GS measurements was assessed in 10 randomly selected 
patients. The coefficient of variation was 8% and the intra-class correlation coefficient was 
0.94 (95% CI = 0.631–0.991).  
 
Measurements of the arterio-ventricular coupling and vascular function 
Effective arterial elastance (Ea) constitutes a “lumped index” of LV afterload in the time-
domain and was calculated as Ea=LVESP / SV; where LVESP is the LV end-systolic 
pressure. LVESP values were estimated as derived from the equation:  
LVESP=0.9 x SBP, where SBP is the systolic systemic blood pressure.[16] LV end-systolic 
elastance (Ees) was calculated using the single-beat approach developed by Chen et al.[17] 
Total arterial compliance was estimated by the SV-to-pulse-pressure ratio[18] and systemic 
vascular resistance index (SVRi) as: mean arterial pressure / cardiac index x 80. 
 
Assessment of LV relaxation rate and filling pressures  
The mean value of the lateral and septal mitral annular early diastolic velocity (e’) was 
determined by spectral tissue Doppler imaging using standard methods. The e’ velocity is 
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relatively preload independent and inversely related to the time constant of isovolumic 
relaxation (tau), which was derived from the previously validated formula:  
tau=(14.70-100 x e’) / 0.15.[19] Early transmitral flow velocity (E) was measured by pulsed-
wave Doppler. LV end-diastolic pressure (LVEDP) was estimated as follows:  
LVEDP=11.96 + 0.596 x E/e’, as previously determined from Doppler and invasive EDP 
measurements.[19]  
 
Determination of LV diastolic stiffness 
The validated single-beat approach [20] was used to characterize the LVEDP – end-
diastolic volume (EDV) relationship (EDPVR) based on the equation:  
EDP=α x EDVβ; where α is a curve-fitting constant and β is the diastolic stiffness 
constant describing the steepness of the EDPVR curve. Measured EDP and EDV were 
used to derive α and β in each subject. Additionally, LV end-diastolic stiffness was 
assessed by the ratio between EDP and EDV.  
 
Ethics 
The study conformed to the Declaration of Helsinki, had ethics approval by local 
ethics committees and all participants provided written informed consent. 
 
Statistics 
IBM SPSS statistics version 23.0 (IBM Corp., Armonk, NY, USA) was used. 
Normality was tested using the Kolmogorov-Smirnov test. Continuous variables were 
expressed as mean ± SD or median and interquartile range (IQR) whereas categorical 
variables as absolute values and percentage.  
Comparisons between groups were performed with Mann-Whitney rank-sum test. 
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Correlations were tested by the Pearson’s 2-tailed test. All tests were performed at 
95% confidence intervals. All p-values were 2-sided and statistical significance was, 
except for the Bonferroni adjusted correlations, set at 0.05. HFpEF patients were 
categorized according to quartiles of LA-GS, and trend tests were applied across the 
groups to investigate the association between LA-GS and demographic characteristics 
and echocardiographic measures of cardiac structure and function. 
The association of LA-GS with the combined outcome of death and/or hospitalization 
was tested with univariate and multivariable Cox proportional hazards models and 
Kaplan and Meier non-parametric test and compared using a log-rank test, using a 
time to event analysis.  Adjustment for demographic and clinical covariates (age, 
history of AF, logST2, eGFR, LV-GLS, LAVi, E/e', and Ea) was performed. The 
proportional hazards assumption was tested for all analyses. No violation of the 
proportional-hazards assumption by LA-GS was found.  
Because of the biomarker levels not being normally distributed, all biomarker data 
were natural logarithmically (log) transformed.  
Analysis of inter-and intra-observer variability was performed for LA-GS in 10 
randomly selected patients by two observers. Methodological error (Err) in a single 
measurement estimated from double measurements was calculated according to 
formula: Err = (SDdiff  x 100%)/(total mean x √2), where SDdiff is the SD of the 
difference between the measurements [21] 
 
RESULTS 
Demographic characteristics of the patient population are provided in Table 1. 
Median EF for the whole cohort was 63% (Q1:57%, Q3:68%). At the time of 
enrollment, all patients were highly symptomatic (88% in New York Heart 
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Association functional class (NYHA) III-IV, 12% in NYHA II status), however, when 
the echocardiographic examination and biochemical analyses were performed (in 
stable state 4-8 weeks after enrollment), the symptoms were significantly alleviated 
(17% in NYHA III, 59% in NYHA II, and 23% in NYHA I; 69% on diuretics).  
Similarly to prior studies in HFpEF, there was a slight overrepresentation of women 
(51% vs. 49%) and nearly half (41%) of the patients demonstrated severe obesity. 52 
patients (60%) had previously been diagnosed with AF, of whom 21 were in AF at the 
time of the echocardiographic examination.  
 
ST2 levels and cardiac mechanics 
The median ST2 concentration in our cohort was 32 ng/mL [Q1:24 - Q3:48 ng/mL]. 
Serum ST2 levels inversely correlated with LA-GS (r=-0.30, p=0.009, Figure 1A). 
However, no association was found between ST2 and the degree of LA enlargement 
(LA volume index, LAVi) or with indices of LV geometrical remodeling (LV mass 
index (LVMi), LV systolic and diastolic volumes), LV systolic functional parameters 
(LV-EF, LV-GLS, Ees), measures of the LV relaxation and end-diastolic function (tau, 
β, EDP/EDV, E/e') or indices of the AV-coupling and the systemic vascular function 
(Ea/Ees, arterial compliance, SVRi). Importantly, an inverse association of ST2 with 
RV function, as assessed by tricuspid annular plane systolic excursion (TAPSE) was 
demonstrated (r=-0.28, p=0.01), whereas no correlation between ST2 and renal 
functional indices (s-Creatinine, eGFR) or CRP was observed. 
 
Determinants of LA strain  
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The LA-GS did not show significant association with the LVMi or LV volumes. 
Although it was significantly related to the SV (r= 0.23 p < 0.05), no correlation with 
other indices of LV systolic performance (LV-EF, LV-GLS; Ees) was evident. 
Similarly, LA-GS was not associated with either the LV end-diastolic function as 
assessed by EDP/EDV ratio, or the β value representing the slope of the EDPVR, or 
the preload as estimated by E/e'. On the other hand, LA-GS was inversely related with 
LV afterload as described by Ea (r=-0.28, p=0.01). Importantly, no significant 
relationship between LA-GS and LAVi was found. Similarly to ST2, LA-GS was also 
significantly associated with TAPSE (r=0.41, P<0.001). In a multiple regression 
analysis, including logST2, age, eGFR, LV-GLS, LAVi, E/e', and Ea as potential 
predictors, only logST2 and eGFR were identified as independent predictors of the 
LA-GS (LA-GS= 39.7 - 5.4 ∗ logST2-0.113xeGFR; p=0.003). However, when the 
occurrence of AF was added in the analysis, eGFR and AF only remained as 
predictors of LA-GS (LA-GS= 29.3 – 7.8 ∗AF-0.092xeGFR; p=0.001). When we 
restricted the above analysis to patients in sinus rhythm, similarly to the entire 
population, only eGFR and logST2 acted as independent predictors of LA-GS (LA-
GS= 2.636 - 0.28 ∗ logST2 - 0.115 x eGFR; p<0.001). 
 
Association between HF symptoms and indices of LA and LV function 
In order to investigate the relationship between the functional status and cardiac 
performance we dichotomized our study cohort into asymptomatic patients (NYHA I, 
n=19) and those with moderate to severe symptoms (NYHA II-III, n=65). LA-GS and 
ST2 were the only markers demonstrating significant difference between the two 
groups (LA-GS: 18.7± 10.7 vs. 11.7±10.8 %, p=0.01; ST2: 30.2±14.1 vs. 42.8± 29.0 
ng/mL, p=0.04, asymptomatic vs. symptomatic patients) [Figure 1]. On the other 
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hand, neither the systolic (LV-GLS, SVi) nor the diastolic LV metrics (β, tau, 
EDP/EDV, E/e’) or AV-coupling and the vascular function indices (Ea, SVRi) differ 
significantly between the two groups [Figure 2]. Additionally, there was no difference 
in NYHA class between patients in sinus and those in AF during the examination 
(p=0.62) 
 
LA strain and outcome 
In order to investigate whether increased LA stiffness as assessed by LA-GS had a 
direct influence on patient prognosis, we dichotomized our patient cohort based on the 
LA-GS, using the third interquartile (LA-GS: 20%) as a cut-off value. 
As shown in Table 2, patients with LA-GS < 20% displayed significantly lower SVi, 
LV-GLS and RV function along with higher Ea. Importantly, E/e' values were similar 
in the two groups. ST2 and NT-proBNP levels were higher in patients with more 
reduced LA-GS, whereas eGFR did not significantly differ between the two groups.  
Over a median follow-up of 572 days (IQR: 467-1369), 32 primary outcome events 
occurred (5 deaths, 27 first HF hospitalizations). No patients were lost to follow-up. 
LA-GS < 20% was associated with an increased risk for the primary composite 
endpoint (p=0.02) in unadjusted analysis [odds ratio (OR) 3.23; confidence interval 
(CI) 1.1-9.3, p=0.029]; Figure 2A. After adjustment for age, eGFR, LV-GLS and tau, 
LA-GS remained an independent predictor of the outcome [OR: 4.15; CI: 1.2-14, 
p=0.023]; Figure 2B.  
As AF impacts on LA functional parameters we proceed by further adjustment 
employing AF as covariate in the aforementioned regression model. LA-GS retained 
its significant predictive ability [OR: 4.56; CI: 1.3-15.7, p=0.016] although significant 
but weaker predictive capacity was even demonstrated for LV-GLS [p=0.042]; in 
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contrast, neither the indices of AV-coupling (Ea, Ees, Ea/Ees) nor the E/e' demonstrated 
any predictive ability for death or hospitalization. In addition, selective analysis of the 
patients in sinus rhythm also showed that, after adjustment for age, eGFR, tau and 
LV-GLS, LA-GS remained an independent predictor of outcome in this population 
[OR: 4.24; CI: 1.2 -14.9, p=0.019]. 
 
DISCUSSION AND CONCLUSION 
In the present prospective study we demonstrate that in HFpEF 1. profibrotic changes 
as indicated by the ST2 biomarker are associated with mechanical alterations of the 
LA but not the LV; 2. the LA strain comprised an independent predictor of death or 
hospitalization independently of the degree of LV remodeling or dysfunction. 
The LA reservoir function is influenced by both LV systolic function and the intrinsic 
LA compliance and plays an important role in disease progression in various 
pathologies including AF, acute myocardial ischemia and HF. LA strain is an 
emerging non-invasive method for the quantification of LA reservoir function.[6] 
LA strain has been shown to reflect the extent of LA fibrosis in various pathological 
states. Kuppahally et al. assessed the degree of LA wall fibrosis by delayed-
enhancement MRI in AF patients and found that LA strain inversely associated with 
the degree of LA fibrosis.[22] In another report, in patients undergoing mitral valve 
surgery, preoperatively measured LA strain was the strongest independent predictor 
of the degree of histopathologically quantified LA wall fibrosis.[23]  
In our study, ST2, an established pro-fibrotic marker, significantly associated with 
LA-GS. Conversely, measures of the systolic-, early diastolic- and late diastolic LV 
function, or those of the AV-coupling and vascular function were not related to ST2 
	 13	
levels. In agreement with our results, previous studies in HFpEF failed to demonstrate 
any relationship between ST2 levels and LV echocardiographic parameters.[14, 24] 
Even though ST2 has repeatedly been shown to be a reliable marker of disease 
severity in HFpEF, the aforementioned observation has led to the misconception that 
elevated ST2 might barely indicate systemic inflammation, rather than reflect direct 
cardiac alterations.[14, 25] No studies, however, have specifically investigated the 
association between LA function and ST2 levels in HFpEF. 
The LV contraction towards the apex is expected to act as a major determinant of the 
LA deformation during systole.[26] In our cohort, however, no association between 
the LV longitudinal deformation and LA-GS was found. This might be explained by 
disparate responses of the LA and the LV to inflammation, as myocardial remodeling 
at the atrial level has been shown to involve differential pathophysiologic pathways 
from the LV. In a tachycardia induced HF model, considerably different cellular 
responses were observed in these two chambers, with more pronounced inflammatory 
and pro-fibrotic reaction detected in the LA as compared to the LV wall.[27] In 
another study, angiotensin–II infusion resulted in progressive LA fibrosis, that was 
independent of LV wall stress but directly related to circulating hormone levels.[28] 
Conceivably, due to its thinner wall, the LA might be more susceptible to myocardial 
fibrosis and exhibit more apparent mechanical changes as compared to LV. Our 
results advocate that LA-GS comprises a surrogate marker of LA mechanical changes 
partly ascribed to a pro-fibrotic reaction and imply that LA structural and functional 
abnormalities might develop on the ground of intrinsic LA alterations, independently 
of LV dysfunction.  
Normally, the distensible LA accommodates blood from the pulmonary veins without 
a considerable rise in the LA pressure (LAP). In cases of reduced LA compliance, as 
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in LA fibrosis, the LA pressure-volume curve is shifted upwards resulting in 
disproportional rise of LAP for the same volume entering the chamber. Chronically 
elevated LAP leads to LA enlargement. Based on physical principles, increased LA 
volume would mitigate the elevated wall stress and accordingly the LAP. 
Paradoxically however, the degree of LA remodeling has been shown to be positively 
related to the severity of pulmonary hypertension.[29] This observation can be 
physiologically explained by concomitantly occurring LA wall fibrosis, which 
counteracts the alleviating effect of LA volume increase. Of note, in the current study, 
LAVi was not associated with either ST2 levels or the LA-GS. Similar findings were 
also reported by others, suggesting that the degree of LA fibrosis is not solely or even 
primarily determined by the degree of LA enlargement,[6, 10] which supports our 
hypothesis that LA fibrosis, as reflected by elevated ST2, might be a result of an 
inflammatory process rather than haemodynamic overload. In our study LA 
enlargement was not associated with the patients functional class either, whereas a 
significant relationship between LA-GS and symptom severity was observed. Similar 
association was also found between ST2 levels and symptomatology, further 
supporting the notion of the potential impact of inflammatory activity on LA 
mechanics.  
LV diastolic properties have been extensively studied in regard to their association 
with symptoms in HFpEF. Employing measurements with conductance catheters, Liu 
et al. demonstrated that HFpEF patients display increased LV end-diastolic stiffness 
and impaired relaxation as compared to healthy controls.[4] These findings were 
confirmed in a larger scale study in which non-invasive estimates of LV relaxation 
and stiffness were used.[8] In another report, however, early relaxation and LV end-
diastolic stiffness were similar between HFpEF patients and healthy subjects at 
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rest[30] and elevated EDP in HFpEF was not accompanied by increased β values 
advocating for the influence of extra-cardiac forces rather than passive LV stiffness 
on the elevated filling pressures. In our study, indices of LV relaxation and diastolic 
stiffness did not correlate with ST2 levels. However, there was a weak association 
between tau and LA-GS suggesting that apart from fibrotic changes, mechanical 
alterations in the LV function during the relaxation phase may also influence the LA 
mechanics.  
 
LA strain and prognosis 
To date few studies have attempted to assess the predictive value of LA function 
regarding outcome in HFpEF. Recently, Melenovsky et al. demonstrated that LA EF 
was an independent predictor of mortality in HFpEF.[7] In another study, Santos and 
colleagues showed that reduced LA strain implied an increased risk for HF 
hospitalization in HFpEF patients, however, it did not remain prognostic after 
adjustment for LV deformation and the E/e'.[31] Accordingly, the authors conclude 
that the predictive ability of LA strain is to be attributed merely to its association with 
LV performance.[31] Importantly, our findings contrast this observation as we show 
that LA-GS independently predicted outcome even when adjusted for measurements 
of LV longitudinal systolic deformation and diastolic performance as well as for 
indices of arterio-ventricular coupling. These disparities might be explained by 
differences in patient profile. Our cohort consisted of older patients, in whom the 
structural and functional LA indices, as well as the higher prevalence of AF indicated 
more advanced disease. Also, in the present work a dedicated software for LA strain 
analysis was employed, presumably yielding more representative measurements, as 
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compared to earlier studies that applied LV strain measuring algorithm for LA strain 
analysis.  
Importantly, in our study other well established indices such as those describing the 
AV-coupling and the E/e’ did not demonstrate significant prognostic value. The later 
non-invasive marker of LA filling pressures has been shown to entail significant 
predictive value in HFpEF. Our findings indicate that LA strain, reflecting not merely 
the hemodynamic filling state but, as previously discussed, also the degree of pro-
fibrotic alterations, constitutes a more robust marker of disease severity in this clinical 
condition. 
AF is a common condition in HFpEF that importantly influences LA-GS 
measurements and thus could be a concern for the reliability and utility of LA-GS 
measurement in these patients. In order to rule out the confounding effect of AF on 
LA-GS measurement, we tested the association of ST2 with LA-GS confining our 
analysis to patients in sinus rhythm. ST2 showed a significant correlation with LA-GS 
in these patients also. Similarly, the independent prognostic value of LA-GS for 
outcome was maintained in this subgroup of patients.  
 
Limitations 
LA strain is a more and more widely used non-invasive metric of LA reservoir 
function; however, the actual haemodynamic meaning of LA strain is rather 
ambiguous. Although the LA deformation during systole is expected to represent a 
surrogate of LA compliance, LA strain is also influenced by other components of the 
cardiac mechanics. A more accurate assessment of the LA reservoir function would 
require direct measurement of LA stiffness by an invasive approach, preferably with 
micro-manometric catheters. On the other hand, the obvious correlations found with 
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both ST2 levels and patient outcome speak for the utility of LA strain, as a readily 
obtainable metric providing clinically important information. The relatively limited 
size of our study, as well as the fact, that out of the 32 outcome events that occurred 
during follow up 27 were heart failure hospitalizations, warrants larger scale 
investigations to confirm our results. At the same time, the prognostic information 
evident even at this patient number corroborates the clinical significance of our 
findings.  
 
Conclusions 
Our results indicate that ST2 is a sensitive marker of LA dysfunction in HFpEF, 
elevation of which may specifically reflect LA mechanical alterations, independently 
of LV performance. Impaired LA strain remained an independent predictor of HF 
hospitalization and mortality, even after adjustment for clinical variables and LV 
functional indices.  
Considering the fact that currently no effective therapy for HFpEF is available, a 
reliable tool for monitoring the evolution of this disease is of major clinical 
significance for the timely recognition and thus prevention of patients at increased 
risk, prior to the development of irreversible LA remodeling. 
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FIGURE LEGENDS 
 
Figure 1. Left atrial strain and ST2 levels. A, correlation between plasma Soluble 
suppression of tumorigenicity-2 receptor (ST2) levels and left atrial strain (LA-GS) 
(r=0.3, p=0.009). B, comparison of ST2 levels between patients with LA-GS < 20% 
and LA-GS ≥ 20%.  
 
Figure 2. Association between heart failure symptoms, echocardiographic 
parameters and ST2 levels. Comparison of left atrial strain (LA-GS) (A), soluble 
suppression of tumorigenicity-2 receptor (ST2) levels (B), left atrial volume index 
(LAVi) (C) and left ventricular global longitudinal strain (LV-GLS) (D) between 
patient groups with (NYHA II-III) or without (NYHA I) heart failure symptoms. 
NYHA, New York Heart Failure Functional Classification. 
 
Figure 3. Left atrial strain and patient outcome. A, Kaplan-Meier analysis of 
patients stratified by left atrial strain (LA-GS). Group I, LA-GS < 20%; Group II, LA-
GS ≥ 20%. B, Hazard ratio for death or heart failure (HF) hospitalization for patients 
with LA-GS < 20% compared to LA-GS ≥ 20%. eGFR, estimated glomerular 
filtration rate; LV-GLS, left ventricular global longitudinal strain; tau, time constant 
of LV isovolumic relaxation; CI, confidence interval.  
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TABLES 
General  
Age years 72 ± 10 
Gender male/female 42/44 (49/51) 
Medical history 
Atrial ﬁbrillation/ﬂutter 52 (60) 
Hypertension 68 (79) 
Diabetes mellitus 28 (33) 
COPD 17 (20) 
Cancer 15 (17) 
Coronary disease 13 (15) 
NYHA I 19 (22) 
NYHA II 46 (53) 
NYHA III 19 (22) 
NYHA IV 0 
Clinical measurements 
BMI kg/m2 30 ± 6 
Obesity (BMI ≥ 30) 34 (41) 
SBP (mm Hg) 142 ± 21 
DBP (mm Hg) 79 ± 9 
HR (beats/min) 70 ± 15 
Treatment 
ARB or ACE-I 65 (76) 
Statin 37 (43) 
Digoxin 10 (12) 
Loop diuretic 59 (69) 
Beta blocker 67 (80) 
Calcium channel blocker 26 (30) 
Laboratory findings 
NT-proBNP (ng/L) 1000 (Q1:465;Q3:2335) 
ST2 (ng/mL) 32 (Q1:24;Q3:48) 
eGFR (mL/min/1.73m2) 70 (Q1:54;Q3:85) 
Hemoglobin (g/L) 13.1 (Q1:12.2;Q3:14.2) 
White blood cell count (109/L) 8.0 (Q1:7.1;Q3:9.9) 
 
Table 1. Demographic data. COPD, Chronic obstructive pulmonary disease; NYHA, New York Heart 
Association functional class; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; HR, heart rate; ARB, angiotensin receptor blocker; ACE-I, ACE-inhibitor; NT-
proBNP, N-terminal pro-brain natriuretic peptide; ST2, soluble suppression of tumorigenicity-2 
receptor; eGFR, estimated glomerular filtration rate. Data are provided as absolute numbers followed 
by percentages in brackets; or median values followed by 1st (Q1) and 3rd (Q3) quartiles in brackets.  
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Entire cohort LA-GS <20% LA-GS ≥ 20 % P-value 
BMI  29.5± 6.0 (57) 30.4 ± 6 (20) NS 
Age  72.8 ± 8 (59) 71.9 ± 10 (20) NS 
SBP (mm Hg)  141 ± 20 (59) 148 ± 22 (20) NS 
DBP (mm Hg)  78 ± 8 (59) 80 ± 11 (20) NS 
LV dimensions     
LV EDVi (mL/m2) 56.6 ± 14 (82) 57.2 ± 15.1 (58) 55.7 ± 12 (20) NS 
LV ESVi (mL/m2) 23.9 ± 11 (82) 25.3 ± 11.2 (58) 20 ± 7 (20) NS 
LVMi (gr/m2) 120 ± 31 (82) 119.6 ± 34 (58) 118 ± 20 (20) NS 
LV systolic function     
LV EF (%) 62.5 ± 7 (82) 61.6 ± 7.6 (58) 65.2 ± 5 (20) NS 
LV-GLS (%) -15.3 ± 3.6 (80) -14.9 ± 3.7 (58) -16.9 ± 3 (18) 0.03 
SVi (mL/m2) 37.4 ± 11 (81) 35.6 ± 10.8 (58) 43.4 ± 10 (19) 0.012 
Ees (mmHg/mL) 2.2 ± 0.9 (81) 2.2 ± 0.9 (58) 2.1 ± 0.8 (19) NS 
LV diastolic function     
E/A ratio 1.8 ± 1.4 (60) 2.2 ± 1.6 (40) 1.1 ± 0.3 (20) 0.008 
e' mean 7.9 ± 2.2 (83) 8.2 ± 2.4 (58) 7.0 ± 1.5 (20) NS 
E/e' mean 12.6 ± 6 (83) 12.7 ± 6.1 (57) 12.7 ± 5 (20) NS 
LV-EDP (mmHg) NI 19.5 ± 3.4 (82) 19.5 ± 3.6 (57) 19.5 ± 2.7 (20) NS 
Tau (ms) NI 45 ± 15 (81) 43.4 ± 15.9 (57) 50.9 ± 10.2 (20) NS 
β 6.0 ± 0.4 (81) 5.98 ± 0.46 (57) 6.03 ± 0.4 (20) NS 
EDP/EDV (mmHg/mL) 0.19 ± 0.06 (81) 0.19 ± 0.1 (58) 0.18 ± 0.04 (20) NS 
Vascular function     
Ea 1.96 ± 0.8 (81) 2.1 ± 0.9 (58) 1.6 ± 0.3 (19) 0.035 
 
Ea/Ees  1.0 ± 0.42 (81) 1.1 ± 0.4 (58) 0.8 ± 0.3 (19) NS 
SVRi (mmHg/L/m2) 47.4 ± 15 (83) 48 ± 16 (58) 46.7 ± 13.2 (20) NS 
Arterial compliance 
(mL/mmHg) 0.72 ± 0.22 (81) 0.69 ± 0.2 (58) 0.83 ± 0.2 (19) NS 
LA function     
LA ESVi (mL/m2) 44.4 ± 16 (79) 44.4 ± 17.1 (59) 44.2 ± 14 (20) NS 
LA-GS (%) 13.3 ± 11 (79) 8.1 ± 6.3 (59) 28.7 ± 7 (20) <0.0001 
LA EF (%) 28.6 ± 18.4 (79) 21.7 ± 15.2 (59) 49.1 ± 10.1 (20) <0.001 
RV function     
TAPSE (mm) 16.5 ± 4 (83) 15.7 ± 4.1 (58) 19.1 ± 4 (20) 0.003 
Biochemical     
NT-proBNP (ng/L)  1400 (Q1:556;Q3:2633)  495 (Q1:430;Q3:822) 0.003 
ST2 (ng/mL)  35.0 (Q1:25;Q3:55) 26.7 (Q1:19;Q3:33) 0.003 
eGFR (mL/min/1.73m2)  70 (Q1:56;Q3:86) 59.5 (Q1:45;Q3:80) NS 
 
	 23	
Table 2. Cardiac and vascular geometric and functional measures in the two groups stratified 
according to LA-GS. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; LV, left ventricle; EDVi, end-diastolic volume index; ESVi, end-systolic volume index; 
LVMi, LV mass index; EF, ejection fraction; LV-GLS, LV global longitudinal strain; SVi, stroke 
volume index; Ees, LV end-systolic elastance; E/A, ratio between the early diastolic inflow velocity 
(E) to the inflow velocity due to atrial contraction (A); e’ mean, mean value of early myocardial 
velocity in LV basal septal and lateral wall; E/e’, ratio between the E and the e´; EDP, end diastolic 
pressure; NI, non-invasive; tau, time constant of LV isovolumic relaxation; β, diastolic stiffness 
constant describing the steepness of the EDPVR curve; EDP/EDV, end diastolic pressure to end 
diastolic volume ratio; Ea, effective arterial elastance; SVRi, systemic vascular resistance index; LA, 
left atrium; LA ESVi, left atrial end-systolic volume; LA-GS, left atrial global longitudinal strain; LA 
EF, left atrial ejection fraction; TAPSE, tricuspid annular plane systolic excursion; NT-proBNP, N-
terminal pro-brain natriuretic peptide; ST2, soluble suppression of tumorigenicity-2 receptor; eGFR, 
estimated glomerular filtration rate; NS, non-significant (p ≥ 0.05). Data are provided as mean ± SD 
followed by patient number in brackets; or median values followed by 1st and 3rd quartiles in brackets. 
 
